Skip to content

Comparison of sublingual buprenorphine and intravenous fentanyl pump for cesarean section pain control

Comparison the therapeutic effects of sublingual buprenorphine and fentanyl intravenous pump for controlling pain after cesarean section with spinal

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017081723559N14
Enrollment
100
Registered
2017-08-20
Start date
2017-11-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

caesarean section. Delivery by elective caesarean section

Interventions

Intervention 1: In the first group, buprenorphine ( Faran shimi Co.) will be administered sublingually at a dose of 0.4 mg and Will be repeated at 6 and 12 hours after the first dose. At the same ti
Treatment - Drugs
In the first group, buprenorphine ( Faran shimi Co.) will be administered sublingually at a dose of 0.4 mg and Will be repeated at 6 and 12 hours after the first dose. At the same time, 100 cc norma
In the second group, the intravenous fentanyl ( Caspian tamin Co.) with a dose of 20 cc per 100 cc of normal saline, will be administered intravenously and continued for up to 24 hours. In this group

Sponsors

Vice chancellor for research, Ardabil University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with spinal anesthesia during cesarean section. Exclusion criteria: History of drug abuse.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: Four times (2,6,12and 24 hours) after intervention. Method of measurement: Visual analog scale.

Secondary

MeasureTime frame
Vomiting. Timepoint: Up to 24 hours after intervention. Method of measurement: Clinical.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Aida Vakili

??????? ???? ????? ??????

a.vakili98@yahoo.com+98 45 3225 1688

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026